Macrophage-stimulating protein (MSP) is a scatter factor that causes cell proliferation and migration, and receptor origin nantaise (RON) is its receptor. RON is expressed in macrophages and mesangial cells, and MSP is produced by renal tubular cells. This study investigated whether MSP/RON participate in the pathogenesis of anti-Thy 1 nephritis, a glomerular disease that is characterized by invasion of circulating monocytes into glomeruli and migration and proliferation of mesangial cells. In vivo, renal function and histopathology were studied in rats that had anti-Thy 1 disease and were untreated and treated with a neutralizing anti-MSP antibody. In vitro, whether monocytes express RON and whether MSP has a chemotactic effect on monocytes were studied. In vivo, in anti-Thy 1 disease, MSP was expressed de novo in glomeruli, and neutralization of MSP attenuated the rise in serum creatinine and proteinuria, stopped glomerular neutrophil and monocyte influx, protected from glomerular injury, and lessened mesangial cell overgrowth. M acrophage-stimulating protein (MSP) is a "scatter factor" that is homologous to hepatocyte growth factor (HGF) (1-3). The receptor of MSP is receptor origin nantaise (RON), a proto-oncogene product (4). Information on the cell source of MSP and the biologic meaning of the MSP/RON system is very limited. Originally, MSP was described as a serum factor produced by hepatocytes that enhanced the chemotactic response of macrophages to the C5a fraction of complement (5-8). It was then demonstrated that MSP induces proliferation, migration, and invasive growth of keratinocytes and epithelial tumor cell lines. These findings have suggested a role of MSP in skin-wound healing and in oncogenesis (8 -15).
M acrophage-stimulating protein (MSP) is a "scatter factor" that is homologous to hepatocyte growth factor (HGF) (1) (2) (3) . The receptor of MSP is receptor origin nantaise (RON), a proto-oncogene product (4) . Information on the cell source of MSP and the biologic meaning of the MSP/RON system is very limited. Originally, MSP was described as a serum factor produced by hepatocytes that enhanced the chemotactic response of macrophages to the C5a fraction of complement (5) (6) (7) (8) . It was then demonstrated that MSP induces proliferation, migration, and invasive growth of keratinocytes and epithelial tumor cell lines. These findings have suggested a role of MSP in skin-wound healing and in oncogenesis (8 -15) .
We have shown that MSP is diffusely expressed in tubular epithelium of human kidney and that proximal tubular cells release MSP. In addition, we have shown that human mesangial cells express RON and that MSP induces in human mesangial cell growth, migration, invasion into an artificial collagen matrix, and synthesis of IL-6 (16) . These findings suggest that MSP, either circulating or as paracrine product, may participate in the pathogenesis of mesangial proliferative glomerulonephritis (e.g., by inducing mesangial cell proliferation, movement, and invasion into the subendothelial space). An additional mechanism of glomerular endocapillary proliferation that may be induced by MSP is the recruitment of circulating monocytes into the glomerulus. In fact, MSP has a chemoattractant action on macrophages that are derived from monocytes. As yet, however, we ignore whether circulating monocytes express RON, and indeed the role of MSP in the pathogenesis of glomerulonephritis or any else inflammatory disease has never been investigated.
This study was performed to understand whether the MSP/ RON system plays a pathogenic role in mesangial proliferative glomerulonephritis. We investigated MSP/RON in anti-Thy 1 glomerulonephritis because in this experimental disease, both proliferation of resident mesangial cells and influx of circulating monocytes into the glomerular tuft (17) (18) (19) are proven pathogenic mechanisms. We aimed also to demonstrate in vitro that monocytes express RON and are attracted by MSP when they are activated, to support the concept that MSP can work in disease as an effector of monocyte recruitment and inflammation.
In Vivo Experiments
Eight week-old female Wistar rats that weighed 160 to 220 g were housed in metabolic cages with free access to water and standard diet. Five groups, each of 15 rats, were studied. Group A rats were administered an intravenous injection at day 0 of 0.5 ml of saline that contained 400 g of anti-Thy 1.1 IgG mAb (Cederlane Laboratories, Ltd., Ontario, Canada). Group B rats were administered an injection at day 0 of anti-Thy 1.1 mAb, followed by 0.5 ml of saline that contained 100 g of anti-MSP IgG goat affinity-purified polyclonal antibody (pAb) that reacted with MSP of rat origin (sc-6090; Santa Cruz Biotechnology, Santa Cruz, CA). Group C rats were administered an injection at day 0 of anti-MSP pAb. Group D rats were administered an injection at day 0 with 0.5 ml of saline. Group E rats were administered an injection at day 0 of anti-Thy 1.1 mAb, followed by 100 g of mixture of goat purified IgG subclasses (Jackson ImmunoResearch, West Grove, PA). In each group, five rats were killed at days 1, 4, and 7. Rats were weighed daily, and 24-h urine was collected and stored at Ϫ20°C. Blood was drawn from the caudal vein at days 0, 1, 4, and 7, and plasma was stored at Ϫ20°C. Soon after the rats were killed, the left kidney was removed, half-fixed in formalin, and half-frozen in liquid nitrogen. MSP Assay. Rat MSP has not been purified, and anti-rat MSP Ab does not cross-react with human MSP (the unique available purified MSP). Therefore, we could not perform a standard curve-based measurement of rat MSP. However, we developed an assay that allowed evaluation of relative changes in MSP levels associated with development of anti-Thy 1 nephritis. Because of interference of the injected anti-MSP Ab with the same anti-MSP Ab used in the assay, MSP levels could be evaluated only in Group A. A total of 50 l of plasma precoated on a microtiter plate was incubated for 1 h at 20°C with goat anti-rat MSP pAb diluted 1:200 in blocking buffer (PBS, BSA 1%, and sodium azide 0.02%). Subsequently, samples were incubated for 1 h at 20°C with biotin-conjugated rabbit anti-goat Ab (Dako, Glostrup, Denmark) diluted 1:5000 in blocking buffer, followed by incubation (1 h) with alkaline phosphatase-conjugated streptavidin diluted 1:2000 in PBS. A colorimetric reaction was developed by addition of p-nitrophenyl-phosphate (Sigma-Aldrich, Milano, Italy) for 30 min at 20°C in the dark. OD was read at 405 nm. The same procedure was used to assay urinary MSP levels, using volumes that contained the same amount of creatinine. MSP levels were expressed as OD at days 0, 1, 4, and 7. To test the reproducibility of the assay, six samples of the same plasma and of the same urine were processed simultaneously (intra-assay variation) and in two different days (interassay variation). The intra-assay variation averaged 2.2 and 2.8%; the interassay variation was 1.1 and 3.8% for plasma and urine, respectively.
Renal Histopathology. Glomerular Injury. Three-micrometer-thick sagittal sections of formalin-fixed kidney were stained with hematoxylin-eosin and were examined by two investigators in a double-blind manner, using a Nikon E400 microscope connected with a DN100 Digital Net Nikon camera (Nikon, Tokyo, Japan). All of the glomeruli in three crosssections of each kidney were examined; their number per section ranged from 84 to 187 (median 122). Neutrophil leukocytes in glomeruli were identified by their morphology at high magnification (ϫ1000) and counted. The following glomerular lesions were distinguished according to Kriz et al. (20) : (1) Mesangiolysis, (2) preballooning, (3) ballooning, (4) microaneurysm, (5) podocyte bridging, (6) tuft adhesion, (7) capillary necrosis, (8) intracapsular hemorrhage, (9) matrix crescent, (10) cellular crescent, (11) capsular rupture, and (12) establishment of a damage score, glomeruli without obvious changes were factored with 0, glomeruli with early lesions (mesangiolysis, preballooning, and ballooning) were factored with 1, and glomeruli with more severe damage (aneurysm, capillary necrosis, tuft adhesion to Bowman's capsule, capsular hemorrhage, capsular rupture, crescent, and glomerular collapse) were factored with 2.
Deposition of Anti-Thy 1.1 mAb. Three-micrometer-thick sections of formalin-fixed tissue were processed by an indirect immunoperoxidase technique, using an antimouse secondary antibody (Dako) to detect the deposited anti-Thy 1.1 mAb. The extent of anti-Thy 1.1 Ab deposition was evaluated in a blinded manner in 40 consecutive glomeruli in each kidney section by image analysis using a Nikon E400 microscope connected with a DN100 Digital Net Nikon camera, Adobe Photoshop 7.0 (Adobe, Uxibridge, UK) and Scion image (Scion Corp., Frederick, MD), according to Uchimura et al. (21) , and graded semiquantitatively according to Floege et al. (22) . In brief, we measured the percentage of glomerular area stained for anti-Thy 1.1 Ab and scored it as follows: I, 0 to 25%; II, 26 to 50%; III, 51 to 75%; and IV, Ͼ75%.
Deposition of C3. The glomerular deposition of C3 complement fraction was detected on 5-m sections of frozen tissue using a direct immunofluorescence procedure with a polyclonal sheep anti-human C3 FITC 1:600 cross-reacting with rat C3 (ICN Pharmaceutical Inc., Irvine, CA). In control sections, nonspecific sheep IgG FITC substituted for the primary antibody. The extent of deposited C3 was evaluated and scored by image analysis as described in the previous section.
Expression of ED-1-Binding Antigen, MSP, Proliferating Cell Nuclear Antigen, ␣-Smooth Muscle Actin, and RON. Three-micrometer-thick sections of formalin-fixed tissue were processed for immunostaining as described previously (23) . The procedure included microwave antigen retrieval (two to four cycles in citrate buffer 0.01 mol/L [pH 6 .0] or EDTA buffer [pH 9], the latter only for MSP). In single immunostaining experiments, the sections were exposed overnight at 4°C to the following antibodies: (1) ED-1 (Serotec, Ltd., Oxford, UK) 1:75; (2) MSP, PCNA, and RON were visualized with the biotin-streptavidinperoxidase complex and colored in 3,3-diaminobenzidine. ED-1-binding antigen (ED-1 Ag) and ␣-SMA were visualized with the alkaline phosphatase complex and colored with Fast Red. All of the cells that were positive for ED-1 Ag and PCNA were counted at high magnification (ϫ400) in all glomeruli in one section of each kidney. In glomeruli of kidneys with anti-Thy 1 disease, the expression of MSP, ␣-SMA, and RON was widespread, and sometimes it was barely possible to distinguish single positive cells. Therefore, we evaluated the glomerular area that stained positively by image analysis rather than the number of positive cells. Double-immunostaining studies were performed to understand whether glomerular cells that expressed RON were monocytes or mesangial cells. The sections were incubated with ED-1 or anti-␣-SMA mAb followed by the secondary Ab and the alkaline phosphatase complex and visualized with Fast Red. Then the same sections were incubated with anti-RON pAb (sc-322; Santa Cruz Biotechnology) diluted 1:8000, followed by the secondary Ab and biotin-streptavidinperoxidase complex, and visualized with 3,3-diaminobenzidine. Negative controls included omission of the primary Ab and substitution of mouse IgG or IgM for primary antibodies.
Renal Function. Plasma creatinine was measured at days 0, 1, 4, and 7 by an automated method (Abbott Laboratories, Abbott Park, IL), and 24-h proteinuria was measured daily by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Richmond, CA).
In Vitro Experiments
Cell Cultures. Peripheral blood mononuclear cells were isolated from rat blood by standard Ficoll-Hypaque gradient centrifugation. Monocytes were collected after 45 min of adherence to plastic culture plates and resuspended in RPMI 1640 medium, FCS 10%, and penicillin/streptomycin 1% (Invitrogen, San Giuliano Milanese, Italy) at 37°C, in humidified 5% CO 2 atmosphere.
Expression of RON Receptor in Monocytes. We studied RON both in circulating monocytes that were examined in whole blood soon after sampling and in monocytes that were isolated from blood and cultured in presence and absence of LPS (10 g/ml) for 24 h. A total of 50 l of EDTA-anticoagulated peripheral blood and 3 ϫ 10 5 monocytes were incubated for 30 min with 10 l of mouse anti-rat RON mAb, diluted 1:10. Subsequently, the samples were incubated for 30 min with 2 l of goat anti-mouse PE conjugated, followed by incubation for 30 min with 2 l of mouse anti-rat CD11b FITC conjugated (BD Biosciences, San Jose, CA), to identify rat monocytes. Incubations were at 4°C in the dark. Before examination, samples of whole blood were treated with lysis buffer. All samples were resuspended in 500 l of PBS and analyzed in FACScan operating with Cell Quest 3.3 software (BD Biosciences). Goat PE-conjugated IgG antibodies were used as negative controls. Effect of MSP on Monocyte Migration. The migration assay was performed in Transwell chambers (Corning, Cambridge, MA). Monocytes (1 ϫ 10 5 cells/well) were seeded on the upper side of a porous polycarbonate membrane (8-m pore size) and were or were not prestimulated with LPS (10 g/ml). The underneath chamber was filled with 500 l of medium alone or supplemented with MSP (30 and 50 ng/ml). After 24 h of incubation, the cells that remained on the upper side of the filter and the cells that passed to the lower chamber were counted. Because only human MPS is available in purified form, these experiments were performed on human monocytes.
Statistical Analyses
ANOVA followed by the Newman-Keuls test or t test was used for comparison of the means. Differences in renal injury scores were evaluated with Mann-Whitney test.
Results

In Vivo Experiments
No significant differences were observed in body weight, water and food intake, and urinary volume among the five groups of rats. Figure 6 . Hematoxylin-eosin staining of representative renal sections at day 7. Groups are as defined in Figure 1 . Necrosis, ballooning, and crescents are prominent in groups A and E in contrast with the other groups. Note also tubular casts in groups A and E. Magnification, ϫ10.
Glomerular Deposition of Anti-Thy1.1 Ab and C3.
In all rats that were administered an injection of anti-Thy1.1 mAb (groups A, B, and E), anti-Thy1.1 Ab and C3 were deposited in glomeruli at day 1 (Figure 1) . Anti-Thy1.1 deposition scored 3.6 Ϯ 0.5, 3.4 Ϯ 0.8, and 3.8 Ϯ 0.6 (mean Ϯ SD) in groups A, B, and E, respectively (P Ͼ 0.05); C3 deposition scored 2.7 Ϯ 1.3, 2.5 Ϯ 0.8, 2.8 Ϯ 1.1 in groups A, B, and E, respectively (P Ͼ 0.05).
Plasma and Urinary Levels of MSP in Rats with Anti-Thy 1 Glomerulonephritis (Group A).
Injection of anti-Thy 1.1 mAb caused a significant rise in urinary levels of MSP at days 1, 4, and 7. Plasma levels of MSP rose significantly at days 4 and 7 ( Figure 2) . Plasma Creatinine. Baseline creatinine was similar in all groups. In groups A and E, creatinine increased significantly at days 1, 4, and 7. In group B, creatinine rose only at days 4 and 7; furthermore, at both days 4 and 7, creatinine was significantly lower in group B than in groups A and E (Figure 3) . Proteinuria. Baseline proteinuria was similar in all groups. In groups A and E, proteinuria rose significantly at day 1, peaked to an eight-fold increment at day 2, and remained significantly higher than at day 0 until day 7. In group B, proteinuria rose significantly only at days 2 and 3, then returned to baseline values. Proteinuria in each single day and peak proteinuria were significantly higher in groups A and E than in group B. Furthermore, cumulative proteinuria (days 0 through 7) was significantly higher in groups A and E than in group B (P Ͻ 0.01), whereas cumulative proteinuria in group B was not significantly different from cumulative proteinuria in groups C and D (Figure 4) .
Histopathology. Glomerular Injury. The typical lesions that were induced by anti-Thy 1.1 mAb are shown in Figure 5 . The prevalence of the various types of lesion in groups A, B, and E is shown in Table  1 . At day 1, in all groups, most glomeruli were normal. At day 4, a minority of glomeruli were normal (i.e., scored 0 in groups A [21.0%] and E [23.7%] in contrast with the majority [73.0%] in group B [P Ͻ 0.0001]). Glomeruli that scored 2 were 32.7% in group A, 34.0% in group E, and 17.8% in group B (P Ͻ 0.005). Significant differences among groups A, E, and B were observed in mesangiolysis and podocyte bridging. The difference in glomerular damage became striking at day 7 (see also Figure  6 ). In fact, at day 7, only 13.0% of glomeruli were normal in group A and 11.7% in group E versus 74.0% in group B (P Ͻ 0.0001). Overall glomerular damage score was much more severe in groups A and E than in group B. In particular, 67.0% of glomeruli scored 2 in group A, 69.0% in group E versus 13.7% in group B (P Ͻ 0.0001). Significant differences between groups A and E and group B were observed in the number of glomeruli that presented preballooning, ballooning, capsular adhesions, podocyte bridging, crescents, capillary necrosis, glomerular collapse, intracapsular hemorrhage, and capsular rupture.
Glomerular Neutrophil Infiltration. In rats of groups C and D, glomerular neutrophils were rare, averaging 0.03 Ϯ 0.01 SD/ glomerulus (G). At day 1, a significant neutrophil infiltration occurred in group A (0.69 Ϯ 0.13/G), E (0.45 Ϯ 0.03/G) and B (0.77 Ϯ 0.16/G; P Ͻ 0.01 versus C and D). At day 4, glomerular neutrophils were more numerous in group A (0.36 Ϯ 0.09/G) and E (0.34 Ϯ 0.07/G) than in group B (0.14 Ϯ 0.04/G; P Ͻ 0.05). At day 7, neutrophil number was not significantly different in groups A, E, B, C, and D.
Glomerular Monocytes Infiltration. As shown in Figure 7 , in groups A and E, the number of glomerular monocytes increased significantly in comparison with groups C and D at days 1 and 4 and rose further at day 7. In contrast, in group B, the number of glomerular monocytes was never higher than in groups C and D and was significantly lower than in groups A and E at days 4 and 7 (P Ͻ 0.01).
Renal Expression of MSP. The expression of MSP was studied in kidneys of rats that were not administered an injection of anti-MSP Ab (i.e., normal rats of group D and rats with anti-Thy 1 disease of group A). In normal kidney, MSP was diffusely expressed in tubules but was not expressed in glomeruli. The injection of anti-Thy 1.1 mAb induced de novo expression of MSP in glomeruli (Figure 8 ). Glomerular MSP expression scored 3.5 Ϯ 0.4 (mean Ϯ SD) at day 1, 2.9 Ϯ 0.8 at day 4, and 2.8 Ϯ 0.6 at day 7 (P Ͼ 0.05).
Glomerular Expression of PCNA, ␣-SMA, and RON. The percentage of PCNA-positive cells was similar in all groups at day 1 (A ϭ 7.0 Ϯ 3.0%, B ϭ 8.0 Ϯ 4.0%, C ϭ 5.0 Ϯ 2.0%, D ϭ 3.0 Ϯ 0.9%, E ϭ 3.5 Ϯ 0.7%). At day 4, PCNA-positive cells increased significantly in groups A and E (18.2 Ϯ 2.0 and 21.0 Ϯ 6.0%, respectively; P Ͻ 0.005) but not in group B (8.0 Ϯ 4.0%) in comparison with groups C and D (3.1 Ϯ 0.8 and 2.3 Ϯ 0.9%, respectively). At day 7, PCNA-positive cells increased in groups A and E (52.0 Ϯ 3.0 and 47.0 Ϯ 10.0%, respectively; P Ͻ 0.001) and in group B (12.0 Ϯ 1.0%; P Ͻ 0.001) compared with control groups (3.3 Ϯ 0.7 and 3.5 Ϯ 1.3%). However, the number of PCNA-positive cells was significantly lower in group B Figure 7 . Glomerular monocytes. Monocytes were stained with ED-1 and counted in all glomeruli present in renal sections. Groups are as defined in Figure 1 . Results are expressed as means Ϯ SD.
# P Ͻ 0.05 versus groups C and D; *P Ͻ 0.01 versus groups B, C, and D. Magnification, ϫ400. than in groups A and E, at both days 4 (P Ͻ 0.005) and 7 (P Ͻ 0.0001).
The expression of ␣-SMA and RON is shown in Table 2 . On days 4 and 7, the percentage of glomerular area that stained for ␣-SMA was significantly higher in groups A, E, and B in comparison with groups C and D. However, the extent of ␣-SMA staining was significantly lesser in group B than in groups A and E. Approximately 1% of glomerular area stained for RON in control groups (C and D); in groups A and E, RON expression rose significantly on days 1 and 4 and peaked to Ͼ80% of the glomerular area on day 7; in group B, RON was expressed more than in control groups but less than in groups A and E on day 7. Double immunostaining demonstrated two distinct glomerular cell populations expressing RON, one prevalent that coexpressed ␣-SMA and consisted of activated mesangial cells (Figure 9) , the other that coexpressed ED-1 Ag and consisted of monocytes ( Figure 10 ).
In Vitro Experiments
RON Expression in Rat Monocytes. Circulating monocytes did not express RON soon after sampling, but RON was detected in a small percentage of monocytes after isolation from blood (7.1 Ϯ 2.6%). After 24 h in culture, RON was detected in 17.5% of monocytes in the presence of LPS compared with 7.1% in its absence (P Ͻ 0.05).
Monocyte Migration Assay. MSP had a powerful chemotactic effect on monocytes that were stimulated with LPS (Figure 11) .
Discussion
This study demonstrates that MSP plays a pathogenic role in anti-Thy 1 disease. In fact, neutralization of MSP attenuated significantly the rise in plasma creatinine and proteinuria and reduced impressively the glomerular lesions, including the most severe ones, such as crescents, capsular adhesions, and capillary necrosis. The neutralization of MSP was associated with a significant decrease of neutrophils that infiltrated the glomeruli and with a powerful inhibition of glomerular monocyte influx. Glomerular infiltration of inflammatory cells is a pivotal pathogenic feature in anti-Thy 1 nephritis (18, 19, 24) ; therefore, inhibition of leukocyte recruitment into the glomerular tuft is a straightforward explanation for the therapeutic effect of anti-MSP Ab in the disease. It is interesting that MSP induces release of superoxide anion in monocyte-derived macrophages (25) ; neutralization of MSP, in addition to limiting the number of invading monocytes, may reduce their harmfulness by decreasing the amount of RON that they release. Neutrophils are ready to respond to MSP because they express the MSP receptor RON constitutively (26) . In contrast, RON is not present on circulating monocytes, so they must express RON de novo to be engaged by MSP. In fact, we found RON in monocytes that infiltrated the glomeruli; in addition, we showed that RON is induced de novo in circulating monocytes that were stimulated in vitro with LPS. These results suggest that in anti-Thy 1 nephritis, the inflamed glomerular environment (27) (28) (29) induces RON in monocytes that circulate locally, so monocytes become responsive to MSP.
In anti-Thy 1 nephritis, urinary and plasma levels of MSP rose, and MSP was extensively expressed de novo in glomeruli. These findings indicate that the inflamed kidneys were a source of MSP and that MSP was released in glomeruli, where it could cause leukocyte accumulation in two ways. One is the chemotaxis operated by MSP itself, as demonstrated by our experiments in vitro. The other one is an indirect mechanism: the sensitization of monocytes to chemoattraction by the C5a fraction of complement, which is abundantly released in glomeruli in anti-Thy 1 nephritis, a complement-dependent disease (17) .
The initial phase of anti-Thy 1 nephritis, characterized by RON (a, brown) , then for ED-1 antigen (b, red-purple). Some monocytes, indicated by the black arrows, stain both in brown and in red-purple. To recognize the red-purple nuance in double-stained monocytes, compare it with the uncontaminated red-purple color of one monocyte that stains for ED-1 antigen but not for RON (red arrow). Magnification, ϫ400.
mesangiolysis, is followed by migration of new mesangial cells from the hilar area (30) and proliferation of migrated cells (17, 18) . These phenomena represent a restorative process but result in a pathologic overgrowth of the mesangium (i.e., in the mesangioproliferative phase of the disease). Actually, in the acute model of anti-Thy 1 nephritis, this phase is self-limited and heals spontaneously (17) ; nonetheless, it remains a potentially pathogenic event. In fact, the unarrested mesangial cell activation and proliferation lead to obliteration of glomerular capillaries and fibrosis in the chronic model of the disease (31) . The neutralization of MSP significantly reduced the rise in glomerular cell number, in PCNA-positive cells, and in cells that expressed ␣-SMA (i.e., attenuated the overgrowth of activated mesangial cells). The repopulation of the mesangium, however, was not prevented because the total number of glomerular cells, the number of PCNA-positive cells, and the number of mesangial cells remained higher than in normal glomeruli.
The lower rate of proliferation in the anti-MSP-treated group may be explained by the lower degree of mesangiolysis in that group. Alternatively, the anti-MSP Ab may have blocked a direct proliferative effect of MSP. In fact, we showed in a previous study that MSP can induce mesangial cell proliferation (16) , and the activated mesangial cells that repopulated the glomeruli expressed RON and were therefore a target for MSP.
Conclusion
Our study demonstrates that MSP has a pathogenic role in anti-Thy 1 nephritis. This finding delineates a new physiognomy of the MSP/RON system: that of a potential actor in inflammatory diseases characterized by monocyte invasion and complement activation.
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